Suchen
Labcorp Holdings Inc
LHZur Watchlist hinzufügen
254.690USD
-2.660-1.03%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
20.96BMarktkapitalisierung
22.41KGV TTM
mehr Informationen über Labcorp Holdings Inc Unternehmen
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Labcorp Holdings Inc Informationen
BörsenkürzelLH
Name des UnternehmensLabcorp Holdings Inc
IPO-datumApr 24, 1991
CEOSchechter (Adam H)
Anzahl der mitarbeiter70000
WertpapierartOrdinary Share
GeschäftsjahresendeApr 24
Addresse358 S Main St
StadtBURLINGTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl27215
Telefon13362291127
Websitehttps://www.labcorp.com/
BörsenkürzelLH
IPO-datumApr 24, 1991
CEOSchechter (Adam H)
Führungskräfte von Labcorp Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
113.14K
+20.91%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
36.49K
+17.78%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+8.75%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
15.04K
+56.95%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
13.78K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
13.74K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
9.85K
+2.92%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
7.88K
+27.39%
Ms. Sandra Dillard van Der Vaart
Ms. Sandra Dillard van Der Vaart
Executive Vice President, Chief Legal Officer, and Corporate Secretary
Executive Vice President, Chief Legal Officer, and Corporate Secretary
5.82K
+62.94%
Ms. Anita Z. Graham
Ms. Anita Z. Graham
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
5.18K
+71.84%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
113.14K
+20.91%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
36.49K
+17.78%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+8.75%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
15.04K
+56.95%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
13.78K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
13.74K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mar 12, 2025
Währung: USDAktualisiert: Mar 12, 2025
FY2021
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Vanguard Capital Management, LLC
6.56%
Victory Capital Management Inc.
6.53%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Investment Management (US)
4.67%
Vanguard Portfolio Management, LLC
4.49%
Andere
72.36%
Aktionäre
Aktionäre
Anteil
Vanguard Capital Management, LLC
6.56%
Victory Capital Management Inc.
6.53%
BlackRock Institutional Trust Company, N.A.
5.40%
State Street Investment Management (US)
4.67%
Vanguard Portfolio Management, LLC
4.49%
Andere
72.36%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.59%
Investment Advisor/Hedge Fund
40.27%
Research Firm
2.57%
Hedge Fund
2.32%
Pension Fund
1.95%
Bank and Trust
1.63%
Sovereign Wealth Fund
1.25%
Family Office
0.74%
Individual Investor
0.41%
Institutionelle Beteiligung
Aktualisiert: Sun, Apr 5
Aktualisiert: Sun, Apr 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
1855
88.74M
108.22%
+5.57M
2025Q4
1846
81.59M
98.42%
-4.50M
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Victory Capital Management Inc.
5.36M
6.5%
+2.72M
+103.11%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.43M
5.37%
+33.59K
+0.76%
Dec 31, 2025
State Street Investment Management (US)
3.83M
4.64%
-5.59K
-0.15%
Dec 31, 2025
Boston Partners
1.91M
2.32%
+660.83K
+52.75%
Dec 31, 2025
Allspring Global Investments, LLC
2.20M
2.68%
+207.96K
+10.42%
Dec 31, 2025
Geode Capital Management, L.L.C.
2.14M
2.59%
+13.78K
+0.65%
Dec 31, 2025
Select Equity Group, L.P.
2.11M
2.56%
+273.74K
+14.90%
Dec 31, 2025
Wellington Management Company, LLP
1.96M
2.38%
-142.69K
-6.78%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares U.S. Healthcare Providers ETF
3.32%
Knowledge Leaders Developed World ETF
2.73%
Thrivent Small-Mid Cap ESG ETF
2.26%
State Street SPDR S&P Health Care Services ETF
1.9%
Schwab Ariel Opportunities ETF
1.62%
Brandes US Value ETF
1.56%
Invesco S&P 500 Equal Weight Health Care ETF
1.52%
Madison Covered Call ETF
1.49%
Nuveen ESG Mid-Cap Value ETF
1.4%
Franklin Genomic Advancements ETF
1.25%
Mehr Anzeigen
iShares U.S. Healthcare Providers ETF
Anteil3.32%
Knowledge Leaders Developed World ETF
Anteil2.73%
Thrivent Small-Mid Cap ESG ETF
Anteil2.26%
State Street SPDR S&P Health Care Services ETF
Anteil1.9%
Schwab Ariel Opportunities ETF
Anteil1.62%
Brandes US Value ETF
Anteil1.56%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.52%
Madison Covered Call ETF
Anteil1.49%
Nuveen ESG Mid-Cap Value ETF
Anteil1.4%
Franklin Genomic Advancements ETF
Anteil1.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
692.30M
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Apr 09, 2026
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2026 going ex on May 29, 2026
May 29, 2026
Jun 11, 2026
May 29, 2026
Jan 14, 2026
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2026 going ex on Feb 27, 2026
Feb 27, 2026
Mar 12, 2026
Feb 27, 2026
Oct 08, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 11, 2025 going ex on Nov 26, 2025
Nov 26, 2025
Dec 11, 2025
Nov 26, 2025
Jul 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 11, 2025 going ex on Aug 28, 2025
Aug 28, 2025
Sep 11, 2025
Aug 28, 2025
Apr 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2025 going ex on May 29, 2025
May 29, 2025
Jun 11, 2025
May 29, 2025
Jan 09, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Mehr Anzeigen
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
